CREST-H Found No Added Cognitive Benefit From Carotid Procedures

CREST-H found no added cognitive benefit from carotid procedures over medication alone. Learn how that differs from decisions about stroke prevention.

CREST-H Found No Added Cognitive Benefit From Carotid Procedures
Share
White Reddit alien mascot face icon on transparent background.White paper airplane icon on transparent background.White stylized X logo on black background, representing the brand X/Twitter.
Oct 24, 2026
Cognitive Health & Protection

On October 19, 2026, Columbia University Irving Medical Center reported that the CREST-H substudy of the CREST-2 randomized clinical trial found no added cognitive benefit from carotid procedures. Published in JAMA on September 16, 2026, the substudy compared restoring blood flow through a procedure with medication alone in people with severe carotid narrowing and no carotid-related symptoms.

The study tested whether restoring blood flow improved thinking

According to Columbia, CREST-H focused on people with asymptomatic carotid stenosis of at least 70%. Asymptomatic means they had no carotid-related symptoms. Researchers assessed cerebral blood flow and cognition at enrollment and one year later.

The American College of Cardiology summary provides the participant counts: 392 people were enrolled in CREST-H and 291 were eligible for analysis. It also reports that 51 participants had reduced cognition at baseline. Those figures distinguish the full enrollment from the group included in the cognitive analysis.

The intervention was revascularization, meaning a procedure intended to restore blood flow. The comparison was between adding a procedure to medical management and using medical management alone. It was not a comparison between receiving care and receiving no treatment.

Columbia reports that cognitive scores improved slightly in both groups. The group receiving a procedure did not improve more than the medication-only group. That difference between groups was the central question, rather than whether either group’s scores changed from its own starting point.

This distinction matters when reading a treatment headline. An improvement after treatment does not by itself show that the treatment provided an added benefit. Here, the comparison group also improved slightly, so the procedural group’s improvement was not enough to establish a cognitive advantage.

Columbia neurologist Randolph Marshall led the substudy. According to Columbia’s account, his team had hoped that improving blood flow would improve cognition based on earlier animal studies and case series. The randomized trial did not show the difference they had hoped to find.

A separate cognitive analysis reached a matching result

The American College of Cardiology also summarized a separate analysis of cognitive outcomes in the CREST-2 trials. It found no significant cognitive advantage from adding stenting or surgery to intensive medical management compared with intensive medical management alone.

That analysis assessed five areas of cognition:

  • Learning
  • Memory
  • Executive function
  • Attention
  • Processing speed

After a mean follow-up of 2.2 years, overall cognitive outcomes and individual test scores were similar between treatment groups. This broader analysis supports the same practical interpretation as CREST-H: adding a procedure did not produce a demonstrated cognitive advantage over medical management.

The ACC summary also addressed CREST-H participants who had reduced cognition at the start. Their scores improved slightly in both treatment groups. The difference between revascularization plus intensive medical management and intensive medical management alone was not significant.

The immediate change is a clearer conversation about treatment goals

For adults concerned about memory or thinking, the practical message is specific. These findings do not support choosing carotid surgery or stenting specifically to reverse cognitive decline in people with severe but asymptomatic carotid narrowing.

That makes the reason for a proposed procedure central to the discussion. A recommendation aimed at preventing stroke answers a different question from a recommendation presented as a way to improve memory. The cognitive findings help patients and clinicians keep those goals separate.

A useful conversation with the treating clinician can focus on questions such as:

  • Is the proposed treatment intended to reduce stroke risk or improve cognition?
  • How do my symptoms and stroke risk affect the recommendation?
  • What treatment options fit my situation?
  • What evidence supports the expected benefit for the outcome we are discussing?

These are questions for shared decision-making, not instructions to select or reject a procedure. The substudy’s cognitive result alone does not settle an individual’s carotid-treatment decision.

For clinicians, the result gives a more precise basis for discussing expectations. A hoped-for improvement in thinking should not be presented as an established added benefit of revascularization for the population studied. Explaining that distinction leaves room to discuss other reasons for treatment without attaching an unsupported cognitive promise.

Memory concerns also deserve their own discussion rather than being folded entirely into a decision about an artery. FitBrainLab’s coverage of memory and focus offers related reading for people trying to understand cognitive-health information.

For researchers, the finding also helps define the next question. The hoped-for link between restoring blood flow and improving cognition did not translate into a better cognitive result in this comparison. Further claims about cognitive benefit need evidence that directly measures that outcome, rather than relying only on the logic behind the intervention.

The cognitive finding is not a verdict on stroke prevention

The strongest caution concerns how broadly the result is applied. CREST-H studied severe but asymptomatic carotid narrowing over one year. Its findings should not be extended to people with symptomatic carotid disease or to other causes of cognitive impairment.

The separate CREST-2 cognitive analysis adds information over its reported follow-up period. It does not turn these findings into a statement about every patient or every possible future outcome. The conclusion belongs to the populations and periods actually studied.

The result also should not be read as evidence that procedures made cognition worse. Columbia reported slight improvements in both groups, with no difference between them. Nor does that shared improvement establish either approach as a general treatment for cognitive decline.

Stroke prevention is a separate part of the evidence. Columbia describes the larger CREST-2 program as a trial of stroke prevention. Its account reports that stenting plus medication decreased strokes two-fold compared with medication alone, while surgery plus medication did not.

That stroke finding and the cognitive finding address different outcomes. A result about stroke reduction is not proof of better memory or attention. A finding of no added cognitive benefit is not proof that a procedure has no role for another clinical reason.

This is why the study should not become a blanket message to decline carotid treatment. Decisions about a procedure belong with the treating clinician in the context of symptoms, stroke risk and treatment options. The same evidence can inform that conversation without supplying the same answer for every person.

The restrained interpretation is also the most useful one. Restoring blood flow was a reasonable idea to test for cognitive benefit. The trial’s value lies in testing that idea against a comparison group rather than treating a plausible explanation as a proven outcome.

Clear treatment goals strengthen long-term cognitive care

CREST-H matters because it separates a hoped-for brain benefit from a demonstrated one. In this study, adding a carotid procedure did not improve cognition more than medical management alone. That finding helps keep expectations tied to the outcome researchers actually measured.

For long-term cognitive health, progress includes learning which interventions do not deliver an expected added benefit. Such results can make future research more focused and clinical conversations more honest. They also help place an individual finding within a broader view of cognitive health protection.

The lasting takeaway is not that vascular treatment lacks value. It is that treating vascular disease and demonstrating a cognitive benefit are distinct claims. Each needs its own evidence.

How FitBrainLab helps

Carotid-treatment decisions rest with patients and their treating clinicians; FitBrainLab puts the cognitive research into language that supports an informed conversation. Its research-led coverage explains brain aging and dementia risk for adults 60+ while distinguishing established findings from uncertain claims about memory and focus.

Explore Resources

Sources

  1. Unclogging Carotid Artery Fails to Improve Cognition
  2. CREST-2, CREST-H: Revascularization Does Not Improve ...

Follow FitBrainLab for research-led insights on memory, focus, brain aging, nutrition and mental fitness after 60. Stay connected for new articles, practical guidance and ideas for a sharper, more engaged life.

White stylized X logo on black background, representing the brand X/Twitter.

Continue reading

November 21, 2026
Cognitive Health & Protection

Healthcare Providers Urged to Screen for Ongoing Loneliness Beyond Household Arrangements

read article
November 20, 2026
Cognitive Health & Protection

Examining How Fourteen Modifiable Risk Factors Across a Lifetime Shape Dementia Prevention

read article
November 19, 2026
Cognitive Health & Protection

Focusing on Daily Connection Rather Than Cognitive Decline When Treating Hearing Loss

read article
lifelong curiosity

Your sharpest years can still be ahead

Build habits that support memory, focus and a curious, connected life.

Read the Blog